Ansell (ANN) Stock Price, Fundamentals & Analysis

What ANN does

Ansell (ANN) is a stock listed on the ASX in the Healthcare sector, specifically in the Medical Instruments & Supplies industry. Headquartered in Richmond, Australia, the company employs 15,000 people and designs, sources, develops, manufactures, distributes, and sells hand and body protection solutions across multiple regions including Asia Pacific, Europe, the Middle East, Africa, Latin America, the Caribbean, and North America. Ansell operates through two segments: Healthcare and Industrial. The Healthcare segment provides surgical gloves, operating room consumables, single-use and examination gloves, and clean and sterile gloves and garments for hospitals, surgical centers, dental surgeries, veterinary clinics, first responders, manufacturers, auto repair shops, chemical plants, laboratories, and life sciences and pharmaceutical companies. The Industrial segment offers hand and chemical protective clothing solutions for automotive, chemical, metal fabrication, machinery and equipment, food, construction, mining, oil and gas, utilities, logistics, and first responders. Its products are sold under brands including ActivArmr, AlphaTec, BioClean, EDGE, ENCORE, GAMMEX, HyFlex, Kimtech, KleenGuard, MICROFLEX, MICRO-TOUCH, RINGERS, SANDEL, and TouchNTuff.

Key numbers explained

• Price and today's change: Ansell trades at 44.21 AUD, up +1.14% today.
• Market cap: The company has a market capitalization of 6.22B AUD.
• Valuation ratios: Ansell has a trailing P/E ratio of 21.5 and a forward P/E ratio of 17.6 based on expected earnings.
• Earnings per share: Trailing 12-month earnings per share (EPS) is 2.06 USD.
• Dividend yield: The dividend yield is 2.62%, with an ex-dividend date of 31 aug. 2松26. The company pays out 38% of its earnings as dividends.
• Risk metric: The beta is 0.6, indicating lower volatility than the market.
• Price range: The 52-week low and high are 25.05 and 44.28 respectively, with a 52-week price change of 39.1%.
• Financials: Trailing 12-month revenue is 2.14B USD with a year-over-year revenue growth of 13.2%. The profit margin is 9.7%, and the operating margin is 15.7%. Return on equity is 10.5%.
• Leverage: The debt-to-equity ratio is 37.4%.
• Asset valuation: The price-to-book ratio is 2.21.
• Earnings: The next earnings date is 24 aug. 2026.

What to watch

• Sector dynamics: Healthcare and Medical Instruments & Supplies are influenced by regulatory changes, technological advancements, and global health trends.
• Market conditions: As a stock listed on the ASX, Ansell is part of the broader Australian market context, which can be compared with peers like Mesoblast (MSB) and Regis Healthcare (REG).
• Financial performance: Revenue growth of 13.2% and a healthy profit margin of 9.7% indicate solid operational performance, while a debt-to-equity ratio of 37.4% suggests manageable leverage.
• Investor considerations: The dividend yield of 2.62% and a payout ratio of 38% may appeal to income-focused investors, while the beta of 0.6 suggests stability.